DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics

Journal of Clinical Oncology

Volumn 34, Issue 25, 2016, Pages 3039-3046

  De Rosa, Nicole ^a,b,c   Rodriguez Bigas, Miguel A ^a,b,c   Chang, George J ^a,b,c   Veerapong, Jula ^a,b,c   Borras, Ester ^a,b,c   Krishnan, Sunil ^a,b,c   Bednarski, Brian ^a,b,c   Messick, Craig A ^a,b,c   Skibber, John M ^a,b,c   Feig, Barry W ^a,b,c   Lynch, Patrick M ^a,b,c   Vilar, Eduardo ^a,b,c   You, Y Nancy ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUOROPYRIMIDINE; FLUOROURACIL; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADULT; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CLINICAL GENETICS; COLON ADENOMA; CONFERENCE PAPER; DNA MISMATCH REPAIR DEFICIENCY; DUODENUM CANCER; ENDOSCOPIC MUCOSAL RESECTION; FEMALE; FOLLOW UP; GERMLINE MUTATION; HEMICOLECTOMY; HUMAN; ILEOSTOMY; KIDNEY CARCINOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROMOTER REGION; PROTEIN DEFICIENCY; QUALITY CONTROL; RECTUM CANCER; RECTUM RESECTION; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UROGENITAL TRACT TUMOR; BENCHMARKING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RECTAL NEOPLASMS; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENCHMARKING; BIOMARKERS, TUMOR; CHEMORADIOTHERAPY, ADJUVANT; DNA MISMATCH REPAIR; FEMALE; FLUOROURACIL; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84983523292     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.66.6826     Document Type: Conference Paper

References (47)

1. Vilar E, Gruber SB: Microsatellite instability in colorectal cancer: The stable evidence. Nat Rev Clin Oncol 7:153-162, 2010
2. Vilar E, Tabernero J: Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov 3:502-511, 2013
3. Stoffel EM, Mangu PB, Gruber SB, et al: Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol 33:209-217, 2015
4. Weissman SM,Burt R,Church J,et al:Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns 21:484-493, 2012
5. Hampel H: Point: Justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Natl Compr Canc Netw 8:597-601, 2010
6. Dineen S, Lynch PM, Rodriguez-Bigas MA, et al: A prospective six sigma quality improvement trial to optimize universal screening for genetic syndrome among patients with young-onset colorectal cancer. J Natl Compr Canc Netw 13:865-872, 2015
7. Beamer LC, Grant ML, Espenschied CR, et al: Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 30:1058-1063, 2012
8. Moreira L, Balaguer F, Lindor N, et al: Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308:1555-1565, 2012
9. Yurgelun MB: Next-generation strategies for hereditary colorectal cancer risk assessment. J Clin Oncol 33:388-393, 2015
10. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003
11. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
12. You YN, Vilar E: Classifying MMR variants: Time for revised nomenclature in Lynch syndrome. Clin Cancer Res 19:2280-2282, 2013
13. Mork ME, You YN, Ying J, et al: High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol 33:3544-3549, 2015
14. Mas-Moya J, Dudley B, Brand RE, et al: Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome. Hum Pathol 46:1616-1625, 2015
15. Carethers JM: Differentiating Lynch-like from Lynch syndrome. Gastroenterology 146:602-604, 2014
16. Hong SP, Min BS, Kim TI, et al: The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. Eur J Cancer 48:1235-1243, 2012
17. Tamas K, Walenkamp AM, de Vries EG, et al: Rectal and colon cancer: Not just a different anatomic site. Cancer Treat Rev 41:671-679, 2015
18. Lim SH, Chua W, Henderson C, et al: Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Crit Rev Oncol Hematol 96:67-80, 2015
19. MD Anderson Cancer Center: Molecular diagnostics laboratory. https://www.mdanderson.org/ education-and-research/resources-for-professionals/ scientific-resources/core-facilities-and-services/ molecular-diagnostics-lab/index.html
20. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758-1762, 1997
21. Thompson BA, Spurdle AB, Plazzer JP, et al: Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet 46:107-115, 2014
22. Reese MG, Eeckman FH, Kulp D, et al: Improved splice site detection in Genie. J Comput Biol 4:311-323, 1997
23. Adzhubei IA, Schmidt S, Peshkin L, et al: A method and server for predicting damaging missense mutations. Nat Methods 7:248-249, 2010
24. Dogan RI, Getoor L, Wilbur WJ, et al: SplicePort-an interactive splice-site analysis tool. Nucleic Acids Res 35:W285-91, 2007
25. Shihab HA, Gough J, Cooper DN, et al: Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat 34:57-65, 2013
26. Schwarz JM, Cooper DN, Schuelke M, et al: MutationTaster2: Mutation prediction for the deepsequencing age. Nat Methods 11:361-362, 2014
27. Myriad Pro: Genetic test results. https:// www.myriadpro.com/for-your-practice/genetic-testresults/
28. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96: 261-268, 2004
29. Kastrinos F, Steyerberg EW, Mercado R, et al: The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 140:73-81, 2011
30. Giardiello FM, Allen JI, Axilbund JE, et al: Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol 109:1159-1179, 2014
31. Samowitz WS, Curtin K, Wolff RK, et al: Microsatellite instability and survival in rectal cancer. Cancer Causes Control 20:1763-1768, 2009
32. Phipps AI, Lindor NM, Jenkins MA, et al: Colon and rectal cancer survival by tumor location and microsatellite instability: The Colon Cancer Family Registry. Dis Colon Rectum 56:937-944, 2013
33. Park IJ, You YN, Agarwal A, et al: Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 30:1770-1776, 2012
34. Brouquet A, Mortenson MM, Vauthey JN, et al: Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: Classic, combined or reverse strategy? J Am Coll Surg 210: 934-941, 2010
35. Lochhead P, Kuchiba A, Imamura Y, et al: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105:1151-1156, 2013
36. Bertolini F, Bengala C, Losi L, et al: Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 68: 1455-1461, 2007
37. Cecchin E, Agostini M, Pucciarelli S, et al: Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neoadjuvant chemo-radiotherapy. Pharmacogenomics J 11:214-226, 2011
38. Charara M, Edmonston TB, Burkholder S, et al: Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res 24:3161-3167, 2004
39. Shin JS, Tut TG, Yang T, et al: Radiotherapy response in microsatellite instability related rectal cancer. Korean J Pathol 47:1-8, 2013
40. Cirillo L, Urso ED, Parrinello G, et al: High risk of rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam criteria. Ann Surg 257:900-904, 2013
41. Vasen HF, Blanco I, Aktan-Collan K, et al: Revised guidelines for the clinical management of Lynch syndrome (HNPCC): Recommendations by a group of European experts. Gut 62:812-823, 2013
42. Wertzberger BE, Sherman SK, Byrn JC: Differences in short-term outcomes among patients undergoing IPAA with or without preoperative radiation: A National Surgical Quality Improvement Program analysis. Dis Colon Rectum 57:1188-1194, 2014
43. Wu XR, Kiran RP, Remzi FH, et al: Preoperative pelvic radiation increases the risk for ileal pouch failure in patients with colitis-associated colorectal cancer. J Crohn's Colitis 7:e419-e426, 2013
44. Coffey JC, Winter DC, Neary P, et al: Quality of life after ileal pouch-anal anastomosis: An evaluation of diet and other factors using the Cleveland Global Quality of Life instrument. Dis Colon Rectum 45: 30-38, 2002
45. Kalady MF, Lipman J, McGannon E, et al: Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer. Ann Surg 255:1121-1125, 2012
46. Lee JS, Petrelli NJ, Rodriguez-Bigas MA: Rectal cancer in hereditary nonpolyposis colorectal cancer. Am J Surg 181:207-210, 2001
47. Win AK, Parry S, Parry B, et al: Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol 20:1829-1836, 2013